UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005392
Receipt number R000006399
Scientific Title Effects of aggressive lipid-lowering therapy in patients with glomerulonephritis
Date of disclosure of the study information 2011/04/11
Last modified on 2021/08/05 18:22:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of aggressive lipid-lowering therapy in patients with glomerulonephritis

Acronym

Statin therapy for glomerulonephritis

Scientific Title

Effects of aggressive lipid-lowering therapy in patients with glomerulonephritis

Scientific Title:Acronym

Statin therapy for glomerulonephritis

Region

Japan


Condition

Condition

glomerulonephritis

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficiency of early statin therapy against urinary protein, renal function and the damage of vascular endothelial cells in patients with glomerulonephritis.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Changes in urinary protein
Changes in eGFR
Changes in ADMA and endothelial lipase

Key secondary outcomes

Serum lipid profile (Total cholesterol,LDL cholesterol, triglyceride) , apolipoprotein, and high-sensitive CRP


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of statins

Interventions/Control_2

No administration of statins

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients with glomerulonephritis
2) Patients with lipid disorder (LDL-C of 100 mg/dl or more)

Key exclusion criteria

1) Allergy against statins
2) Pregnant
3) Patients judged as being inappropriate for this study by investigators

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Shinichi
Middle name
Last name Nishi

Organization

Kobe University School of Medicine

Division name

Division of Nephrology & Kidney Center

Zip code

650-0017

Address

7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017 Japan

TEL

078-382-6500

Email

snishi@med.kobe-u.ac.jp


Public contact

Name of contact person

1st name Kentaro
Middle name
Last name Nakai

Organization

Kobe University School of Medicine

Division name

Division of Nephrology & Kidney Center

Zip code

650-0017

Address

7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017 Japan

TEL

078-382-6500

Homepage URL


Email

kentaro-kyu@umin.org


Sponsor or person

Institute

Division of Nephrology & Kidney Center, Kobe University School of Medicine.

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kobe University School of Medicine

Address

7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017 Japan

Tel

078-382-5045

Email

rinri@med.kobe-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

神戸大学医学部附属病院


Other administrative information

Date of disclosure of the study information

2011 Year 04 Month 11 Day


Related information

URL releasing protocol

https://endai.umin.ac.jp/cgi-open-bin/ojac/search/ojac_search.cgi?cond=%27A00018-00058-20324%27&&&pa

Publication of results

Unpublished


Result

URL related to results and publications

https://endai.umin.ac.jp/cgi-open-bin/ojac/search/ojac_search.cgi?cond=%27A00018-00058-20324%27&&&pa

Number of participants that the trial has enrolled

21

Results

At the time of remission of urinary protein, both groups showed a trend toward improvement in lipid abnormalities, but EL, which was not significantly different at the time of initiation of steroid therapy, remained higher in group A than in group C from the time of remission until 1 month later. After 3 months of remission, EL was similar in the two groups, but tended to be higher than at the beginning of treatment in both groups.

Results date posted

2021 Year 08 Month 05 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Twenty-one consecutive patients with clinically determined MCNS who gave consent were randomized to receive atorvastatin (group A) or control (group C) for comparison.

Participant flow

Fifteen patients were diagnosed by renal biopsy as MCNS, one as membranous nephropathy, and four did not undergo renal biopsy. Twelve patients (60%) were male, and the median age was 42 years.

Adverse events

None

Outcome measures

At the time of remission of urinary protein, both groups showed a trend toward improvement in lipid abnormalities, but EL, which was not significantly different at the time of initiation of steroid therapy, remained higher in group A than in group C from the time of remission until 1 month later. After 3 months of remission, EL was similar in the two groups, but tended to be higher than at the beginning of treatment in both groups.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2011 Year 04 Month 06 Day

Date of IRB

2011 Year 04 Month 06 Day

Anticipated trial start date

2011 Year 09 Month 01 Day

Last follow-up date

2016 Year 03 Month 31 Day

Date of closure to data entry

2016 Year 03 Month 31 Day

Date trial data considered complete

2016 Year 03 Month 31 Day

Date analysis concluded

2016 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2011 Year 04 Month 06 Day

Last modified on

2021 Year 08 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006399


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name